Search Results - life+sciences+%3e+therapeutics+%3e+formulation

40 Results Sort By:
Intranasal Levothyroxine Formulation
Eliminates variable oral bioavailability: Intranasal levothyroxine powder delivers 2x mucosal permeation. This technology is a stable, intranasal dry powder formulation of levothyroxine free acid designed to improve absorption and avoid degradation, offering a more reliable alternative to oral thyroid hormone therapy for hypothyroidism. Background Hypothyroidism...
Published: 5/12/2026   |   Updated: 5/12/2026   |   Inventor(s): Hugh Smyth, Nila Murali, Matthew Herpin, Eldina Memic
Keywords(s):  
Category(s): Life sciences > Therapeutics > Formulation
Simvastatin In-Situ Gel
Thermoresponsive nanoscale intranasal delivery system for enhancing direct nose-to-brain drug delivery This technology is an intranasal gel spray that uses nanoscale simvastatin particles and mucoadhesive, thermoresponsive gel to improve brain drug delivery, increase nasal retention, and bypass first-pass metabolism for better treatment of neurological...
Published: 5/12/2026   |   Updated: 5/12/2026   |   Inventor(s): Hugh Smyth, Jailen Doyle, Molly Levine
Keywords(s):  
Category(s): Life sciences > Therapeutics > Formulation
Inhaled dry powders of nucleic acid-polymer polyplexes
Eliminates mRNA cold chain delivering inhalable powders with 71% aerosol efficiency. This technology creates stable, inhalable dry powders of mRNA-polymer complexes using thin-film freeze-drying, enabling room-temperature storage and efficient pulmonary delivery of RNA therapeutics, including CRISPR, for treating lung diseases without the need for...
Published: 5/11/2026   |   Updated: 5/11/2026   |   Inventor(s): Zhengrong Cui, Bhupendra Giri, Philip Santangelo, Chiara Zurla, Donald Owens, Gregory Davenport, Chaeho Moon
Keywords(s):  
Category(s): Life sciences > Therapeutics > Drug delivery, Life sciences > Therapeutics > Formulation
Thin-film freeze-dried antibiotic powders for fixed-dose pulmonary delivery
Background Pulmonary diseases such as nontuberculous mycobacterial infections and chronic obstructive pulmonary disease (COPD) remain major global health challenges, often requiring long-term antibiotic therapy delivered directly to the lungs to achieve effective pathogen clearance. Inhaled drug delivery provides a promising approach to increase local...
Published: 1/30/2026   |   Updated: 1/30/2026   |   Inventor(s): Zhengrong Cui, Reem Zaki, Michael Sandoval, Robert Williams, Jay Peters
Keywords(s):  
Category(s): Life sciences > Therapeutics > Formulation, Life sciences > Therapeutics > Drug delivery
Sulfonyl-triazole activators for cell-selective glycolysis enhancement in cancer and Parkinson’s disease
Background Cellular metabolism is a central regulator of immune cell function and neuronal survival, making it a promising therapeutic target in both cancer and neuro­degenerative disease. In solid tumors, tumor-infiltrating lymphocytes (TILs) frequently succumb to metabolic exhaustion due to the nutrient-depleted and immunosuppressive microenvironment,...
Published: 1/27/2026   |   Updated: 1/27/2026   |   Inventor(s): Ku-Lung Hsu, Xiaoding Jiang, Xiaolu Cambronne
Keywords(s):  
Category(s): Life sciences > Therapeutics > Formulation, Life sciences > Therapeutics > Drug discovery
Spray-dried RNA-lipid nanoparticle dry powder technology for stable and inhalable delivery of therapeutics
Background Messenger RNA (mRNA) therapeutics have rapidly emerged as a transformative method for vaccination and gene therapy. However, the field faces significant hurdles related to the instability of mRNA molecules, which are highly susceptible to enzymatic degradation. Lipid nanoparticles (LNPs) have become the delivery vehicle of choice, shielding...
Published: 1/27/2026   |   Updated: 1/27/2026   |   Inventor(s): Zhengrong Cui, Bhupendra Giri, Hugh Smyth
Keywords(s):  
Category(s): Life sciences > Therapeutics > Manufacturing platform, Life sciences > Therapeutics > Formulation
Sulfonyl-purine probes for covalent targeting of lysine and tyrosine in drug discovery
Background A significant portion of the human proteome remains inaccessible to traditional drug discovery approaches, particularly proteins lacking reactive cysteines or well-defined binding pockets. These so-called “undruggable” targets present major challenges for small molecule therapeutics, limiting the development of treatments for...
Published: 1/13/2026   |   Updated: 12/4/2025   |   Inventor(s): Ku-Lung Hsu, Zhihong Li
Keywords(s):  
Category(s): Life sciences > Therapeutics > Formulation, Life sciences > Research tools > Reagent
Dual-action topical formulations for enhanced skin penetration and targeted dermal repair
Background Dermatological and cosmetic treatments increasingly focus on targeted delivery of active compounds to the deeper skin layers to combat photoaging, oxidative damage, and carcino­genesis. However, the stratum corneum presents a formidable barrier to percutaneous absorption, limiting the efficacy of topically applied actives. Conventional...
Published: 1/13/2026   |   Updated: 8/14/2025   |   Inventor(s): Hugh Smyth, Patricia Martins
Keywords(s):  
Category(s): Life sciences > Therapeutics > Formulation, Life sciences > Therapeutics > Drug delivery
High-dose dry powder inhaler for dual pulmonary and oral indomethacin delivery
Background Dry powder inhalers (DPIs) offer a non-invasive and rapid route for drug delivery, particularly for medications requiring swift systemic action. This is especially relevant for poorly soluble drugs such as indomethacin, where oral admini­stration is often limited by gastrointestinal degradation and adverse side effects. For indications...
Published: 1/13/2026   |   Updated: 8/14/2025   |   Inventor(s): Hugh Smyth, Jamie Spahn, Feng Zhang
Keywords(s):  
Category(s): Life sciences > Therapeutics > Formulation, Life sciences > Therapeutics > Drug delivery
Inhalable vancomycin–DNase powder for eradication of MRSA lung infections
Background Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of hospital-acquired pneumonia, contributing to elevated mortality, prolonged hospitalizations, and increased healthcare costs. The persistence of MRSA in the lungs is largely due to its ability to form biofilms and generate persister cells, both of which protect the bacteria...
Published: 1/13/2026   |   Updated: 8/14/2025   |   Inventor(s): Hugh Smyth, Rex Moore
Keywords(s):  
Category(s): Life sciences > Therapeutics > Formulation
1 2 3 4